References
- Assis DN, Navarro VJ. (2009). Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 5:463–73.
- Chen M, Suzuki A, Borlak J, et al. (2015). Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 63:503–14.
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
- Kaku K. (2013). Fasiglifam as a new potential treatment option for patients with type 2 diabetes. Expert Opin Pharmacother 14:2591–600.
- Kaku K, Enya K, Nakaya R, et al. (2015). Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 17:675–81.
- Kaku K, Enya K, Nakaya R, et al. (2016). Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study. Diabetes Obes Metab 18:925–9.
- Leifke E, Naik H, Wu J, et al. (2012). A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 92:29–39.
- Li X, Zhong K, Guo Z, et al. (2015). Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury. Drug Metab Dispos 43:1751–9.
- Miners JO, Smith PA, Sorich MJ, et al. (2004). Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1–25.
- Naik H, Vakilynejad M, Wu J, et al. (2012). Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52:1007–16.
- Negoro N, Sasaki S, Mikami S, et al. (2010). Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 1:290–4.
- Strassburg CP, Oldhafer K, Manns MP, Tukey RH. (1997). Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212–20.
- Tsujihata Y, Ito R, Suzuki M, et al. (2011). TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339:228–37.
- Tukey RH, Strassburg CP. (2001). Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405–14.
- United States Department of Health and Human Services Food and Drug Administration. (2009, July). Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/UCM174090.pdf [last accessed 19 Jul 2017].
- van Staden CJ, Morgan RE, Ramachandran B, et al. (2012). Membrane vesicle ABC transporter assays for drug safety assessment. Curr Protoc Toxicol 54:1–24.
- Watkins PB. (2011). Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 89:788–90.
- Wolenski FS, Zhu AZ, Johnson M, et al. (2017). Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury. Toxicol Sci 157:50–61.